Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin R Bailey

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|May 19, 2022
Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potencyNicole Frumento, Alexis Figueroa, Tingchang Wang, et al.
Science Advances|August 8, 2018
CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humansRamy El-Diwany, Mary Soliman, Sho Sugawara, et al.
Cell Host & Microbe|November 16, 2018
Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus InfectionValerie J Kinchen, Muhammad N Zahid, Andrew I Flyak, et al.
Medrxiv : the Preprint Server for Health Sciences|November 3, 2020
Durable SARS-CoV-2 B cell immunity after mild or severe diseaseClinton O Ogega, Nicole E Skinner, Paul W Blair, et al.
The Journal of General Virology|January 13, 2026
Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independentJessica L Mimms, Ariadne Sinnis-Bourozikas, Nathaniel R Felbinger, et al.
Immunity|March 22, 2024
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearanceClinton O Ogega, Nicole E Skinner, Marta V Schoenle, et al.
The Journal of Clinical Investigation|February 11, 2021
Durable SARS-CoV-2 B cell immunity after mild or severe diseaseClinton O Ogega, Nicole E Skinner, Paul W Blair, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
mAbClust with AlphaFold 3 avoids hallucinations to define a quaternary broadly neutralizing HCV epitopeHarry T Paul, Jessica L Mimms, Hanna Aboueid, et al.
JCI Insight|May 5, 2017
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceJustin R Bailey, Andrew I Flyak, Valerie J Cohen, et al.
Journal of Hepatology|July 10, 2024
Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 aloneJuthika Kundu, Hoa T Le, Michael Logan, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|May 19, 2022
Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potencyNicole Frumento, Alexis Figueroa, Tingchang Wang, et al.
Science Advances|August 8, 2018
CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humansRamy El-Diwany, Mary Soliman, Sho Sugawara, et al.
Cell Host & Microbe|November 16, 2018
Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus InfectionValerie J Kinchen, Muhammad N Zahid, Andrew I Flyak, et al.
Medrxiv : the Preprint Server for Health Sciences|November 3, 2020
Durable SARS-CoV-2 B cell immunity after mild or severe diseaseClinton O Ogega, Nicole E Skinner, Paul W Blair, et al.
The Journal of General Virology|January 13, 2026
Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independentJessica L Mimms, Ariadne Sinnis-Bourozikas, Nathaniel R Felbinger, et al.
Immunity|March 22, 2024
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearanceClinton O Ogega, Nicole E Skinner, Marta V Schoenle, et al.
The Journal of Clinical Investigation|February 11, 2021
Durable SARS-CoV-2 B cell immunity after mild or severe diseaseClinton O Ogega, Nicole E Skinner, Paul W Blair, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
mAbClust with AlphaFold 3 avoids hallucinations to define a quaternary broadly neutralizing HCV epitopeHarry T Paul, Jessica L Mimms, Hanna Aboueid, et al.
JCI Insight|May 5, 2017
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceJustin R Bailey, Andrew I Flyak, Valerie J Cohen, et al.
Journal of Hepatology|July 10, 2024
Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 aloneJuthika Kundu, Hoa T Le, Michael Logan, et al.
Pageof 9